A. Kern

发表

Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent

R. Gil, A. Witkowski, M. Lesiak, 2019, Medicine.

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study

J. Wójcik, G. Specchia, A. Budaj, 2021, Cardiology journal.

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

T. Stompór, D. Onichimowski, J. Kiewisz, 2021, Journal of personalized medicine.

Association of serum sclerostin concentrations and atherosclerosis advancement in patients referred to invasive coronary angiography.

T. Stompór, J. Kiewisz, J. Bil, 2020, Kardiologia polska.

Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry

R. Gil, T. Pawlowski, J. Bil, 2020 .

Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.

R. Gil, J. Bil, A. Kern, 2013, Cardiology journal.

Platelet distribution width as the prognostic marker in coronary bifurcation treatment

R. Gil, B. Januszko-Giergielewicz, J. Bil, 2017, European journal of clinical investigation.

Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS® stents for coronary bifurcation treatment: four-year results of randomized POLBOS I and POLBOS II clinical trials.

R. Gil, J. Bil, A. Segiet, 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Complete Blood Count-Derived Indices as Prognostic Factors of 5-Year Outcomes in Patients With Confirmed Coronary Microvascular Spasm

R. Jalali, D. Onichimowski, J. Bil, 2022, Frontiers in Cardiovascular Medicine.

6‐year results of BiOSS stents in coronary bifurcation treatment

R. Gil, J. Bil, S. Dobrzycki, 2021, European journal of clinical investigation.

Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II

R. Gil, J. Bil, S. Dobrzycki, 2018, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.

P. Serruys, J. Wykrzykowska, R. Gil, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Five-year clinical outcomes following drug-eluting stent implantation in left main trifurcations

R. Gil, J. Bil, S. Dobrzycki, 2019, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.

R. Gil, J. Bil, A. Segiet, 2013, Cardiology journal.

Posterior reversible encephalopathy syndrome (PRES) in the course of immunosuppressive therapy in A 45-year-old male with normal blood pressure – case study

R. Jalali, E. Bandurska-Stankiewicz, P. Olsztyn, 2018 .

Coronary microcirculation dysfunction in patients with arterial hypertension

J. Bil, M. Zaleska, O. Możeńska, 2018, Arterial Hypertension.